PLX Protalix BioTherapeutics, Inc.

1.14
0  -2%
Previous Close 1.16
Open 1.17
Price To book 0.00
Market Cap 141.51M
Shares 124,134,000
Volume 2,143,387
Short Ratio 0.93
Av. Daily Volume 4,032,410

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved May 1, 2012.
Taliglucerase alfa
Gaucher disease
Phase 3 dosing commenced October 2016. Enrollment to be completed 2H 2017 with data in 2018.
PRX-102
Fabry disease
Phase 2 interim data released January 3, 2017. Full data due first half of April 2017. April 14 noted as estimated final possible date due to guidance of "first half April".
AIR DNase (PRX-110)
Cystic Fibrosis
Phase 2 trial initiation announced November 30, 2016. Data due around the end of 2017.
OPRX-106
Ulcerative Colitis

Latest News

  1. PROTALIX BIOTHERAPEUTICS, INC. Financials
  2. Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  3. PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
  4. Protalix BioTherapeutics Reports 2016 Full Year Results and Provides Corporate Update
  5. Q4 2016 Protalix Biotherapeutics Inc Earnings Release - Time Not Supplied
  6. Cerulean Pharma Attracts Investors and Possible Suitor, Protalix Returns to the Spotlight
  7. Today's Research Report on Trending Biotech Tickers: Protalix Biotherapeutics and Stemline Therapeutics
  8. Protalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16, 2017
  9. Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta
  10. PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure
  11. PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Shareholder Director Nominations
  12. Protalix BioTherapeutics Announces Record Date for the 2017 Annual Meeting of Stockholders
  13. Protalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium™ 2017
  14. M&A Activity Could Kick Start Biotech Industry's Recovery in 2017: Today's Report on Benitec and Protalix
  15. Protalix BioTherapeutics (PLX) Jumps: Stock Rises by 11.7%
  16. PROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Discl
  17. Protalix BioTherapeutics Provides Review of 2016 and Strategic Outlook for 2017
  18. Protalix BioTherapeutics Announces Positive Interim Results from Phase II Clinical Trial of alidornase alfa (AIR DNase™) for the Treatment of Cystic Fibrosis
  19. Protalix BioTherapeutics Receives Confirmation of Order for over $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil
  20. Protalix BioTherapeutics Receives Letter Detailing Intended Purchases of Approximately $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil